Resources at emerging growth companies are often more constrained than those of large cap, public companies, but the governance challenges remain the same. In today’s environment of fast-moving megatrends such as social media, digital technological change, heightened investor expectations and workforce transformation, the already challenging corporate governance landscape moves board risk assessment to a new level at the emerging growth company.
Join the NACD Philadelphia Chapter to discuss how emerging growth companies are incorporating today’s megatrends into their strategic plans to optimize culture, the bottom line and future growth. In addition, we’ll discuss the imperative communication between the executive team and the board to ensure risks related to these trends are being appropriately mitigated.
Manu is Co-FOunder and CEO of Snapyr, a stealth digital marketing technology start-up. He has been a digital entrepreneur for three decades and is currently building his 5th startup. His passions lie in gaming, digital marketing and artificial intelligence. He is also an active early stage investor and very engaged helping the companies he is involved with create a comprehensive, yet agile governance and decision-making structure.
He is currently collaborating with India’s leading gaming company, Play Games 24X7 Private Limited, to build the world’s first AI-driven visual programming language for digital marketers.
Manu graduated from the University of Pennsylvania with degrees in Entrepreneurship and Computer Science Engineering.
Jane is a founding Managing Partner of Militia Hill Ventures (MHV), an organization that creates, builds and invests in life sciences companies developing cutting edge science. While at MHV, Jane co-founded and served as Executive Chair of Talee Bio, a gene therapy company with a focus on cystic fibrosis, and served as Executive Chair and CEO of Immunome Inc., a cancer immunotherapy company.
Prior to MHV, Jane was co-founder and CEO of NuPathe Inc., a publicly-traded biopharmaceutical company focused on diseases of the central nervous system and sold to Teva in 2014. She also co-founded and served as EVP of Auxilium Pharmaceuticals, a biopharmaceutical company focused on urology and sold to Endo Pharmaceuticals in 2015. Prior to launching and leading multiple successful biopharmaceutical companies, Ms. Hollingsworth was VP, Secretary & General Counsel of IBAH, Inc., a publicly-traded, multinational clinical research organization.
Before joining IBAH, she practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.
Hollingsworth is one of the leaders of the entrepreneurial and life sciences communities and serves in various industry and community boards, including DS Biopharma, Afimmune Ltd., the University City Science Center, the Kimmel Center for the Performing Arts and Breastcancer.Org.
Jason Monteleone is Chief Executive Officer of Clinipace, a global, full service Clinical Research Organization (CRO). Jason joined Clinipace in 2017 to build a CRO with personalized services and solutions, local regulatory expertise and therapeutic leadership that delivers with a level of collaboration and flexibility not possible in a traditional CRO environment. Clinipace leverages its Clarity Stack technology platform to improve clinical trial operations through interoperability, helping sponsors make more informed decisions, improve compliance and identify issues faster. Clinipace has experience with the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, and nephrology and urology.
Jason is also the founder of Pivotal Financial Consulting, LLC, providing strategic advisory services to private equity firms and life science companies. Jason was an advisor on several recent CRO transactions, including Metalmark Capital’s acquisition of Premier Research, Court Square Capital’s acquisition of Celerion and Genstar Capital’s acquisition of Bracket Global. Pivotal is also currently providing CFO advisory services to a local biotech.
Prior to joining Clinipace and founding Pivotal, Jason divested Omnicare Clinical Research (OCR) from Omnicare, Inc. (a Fortune 500 company) to Nautic Partners, a middle market private equity firm. Post transaction, OCR was renamed Theorem Clinical Research and Jason was appointed Executive Vice President and Chief Financial Officer. Jason was part of a management team that doubled Theorem’s revenue and orchestrated an exit resulting in a 20x return multiple for Theorem’s investors.
Jason has over 20 years experience in the healthcare and life science sectors primarily with small to mid-size companies. He attained his undergraduate degree in Business Administration from Millersville University and his Masters in Business Administration (MBA) at Temple University. Jason is also both a Certified Public Accountant (CPA) and Certified Management Accountant (CMA).
Wendy DiCicco is an experienced C-suite executive and a corporate director with an array of corporate leadership accomplishments with both public and private companies. She currently serves on the boards of EyePoint Pharmaceuticals (NASDAQ: EYPT), where she serves as the Audit Committee Chair, and Carmell Therapeutics. She has previously served on three additional corporate boards, including boards in the medical device, semiconductor and biotechnology sectors, where she has experience chairing the audit, compensation and governance committees Ms. DiCicco is also a Financial, Executive and Board Advisory Consultant for several emerging growth companies.
At the C-level, she brings broad, practical leadership experience including financial and operational acumen as a CFO, COO and President for both public and private companies. Most recently, Ms. DiCicco was the Chief Operating and Chief Financial Officer of Centinel Spine and previously the President and Chief Operating Officer at Camber Spine Technologies. Prior to these two privately held spinal technology companies, Ms. DiCicco served as the Chief Financial Officer for several private and public medical device and biotechnology companies.
Ms. DiCicco started her career with Deloitte & Touche in audit assurance. Ms. DiCicco also serves in the community, where she is currently on the board of the Philadelphia Chapter of the National Association of Corporate Directors (NACD) and the Chester County Library System. She is a Corporate Governance Fellow as well as a Board Leadership Fellow of the NACD. Ms. DiCicco graduated from Philadelphia College of Textiles and Science with a B.S. degree in Accounting and is a CPA in the state of Pennsylvania.